Milestones 4474

May 1, 2008

2 Min Read



St. Jude Medical Inc. (St. Paul, MN) and EP MedSystems Inc. (West Berlin, NJ) have announced a definitive merger agreement under which St. Jude Medical will acquire EP MedSystems for approximately $92.1 million. "This transaction will ac-celerate the growth of St. Jude Medical's program to help physicians cure atrial fibrillation," said Daniel J. Starks, chairman, president, and CEO of St. Jude Medical.


Stentys (Paris), which has developed a stent for treatment of blocked coronary artery bifurcations, has completed an $18 million series B round of venture financing. "This financing round will allow us to complete clinical trials and obtain the CE mark for our drug-eluting bifurcated stent, enabling interventional cardiologists to offer their patients the next generation of dedicated bifurcated-stenting procedures," said Gonzague Issenmann, Stentys' CEO and cofounder.


Affinergy Inc. (Research Triangle Park, NC), a Duke University spinout that develops site-specific biological delivery systems, has been awarded five new small business innovation research (SBIR) grants, including a phase 2 SBIR program for more than $2 million. The phase 2 grant is funded through the National Institute of General Medical Sciences. The focus of the program is to advance development and optimization of Affinergy's peptide linkers to accelerate a patient's natural healing processes. "This further validates our technology as reviewed by scientific peers and acknowledges the progress that was demonstrated by our staff during the previous 18 months," said Jonathan Gindes, Affinergy's CFO and senior vice president of business development.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like